Recent world events have demonstrated the growing demand for next-generation biomanufacturing solutions that are both high-yielding, highly flexible and cost effective and that deliver high-quality drug products. WuXi Biologics’ ultrahigh productivity platform (WuXiUP), an intensified perfusion culture process, was developed to meet the aforementioned need. The following article outlines our unique continuous manufacturing approach and how it can improve and impact biomanufacturing in the future
